Hematopoietic cancers are dealt with tumours of immune system cells. Most of them are encompassed of cells that are functionally heterogeneous with only a subdivision being in charge for tumor care. Leukemias are “liquid tumors” in the blood and are derived from the transformation of either a hematopoietic precursor in the bone marrow or a mature hematopoietic cell in the blood. Leukemias can be lymphoid or myeloid, and acute or chronic.
Most hematopoietic malignancies are comprised of cells that are functionally heterogeneous with only a subset being responsible for tumor maintenance.
The thorough perceptive of accumulation of genetic/epigenetic event progressions could prime to development of therapeutics that more effectively treat hematopoietic malignancies and potentially other cancers.
Hematopoietic cancers (HCs) are malignancies of immune system cells, associated with gross chromosomal abnormalities such as translocations.
Improvements in diagnosis and therapy, including hematopoietic stem cell transplantation and molecularly targeted strategies, have increased patient survival.
- Hematopoietic Cancer
- Recurring Translocation
- Hodgkin Lymphoma
- Non-Hodgkin lymphoma
Related Conference of Hematopoietic Malignancies
Hematopoietic Malignancies Conference Speakers
- Biomarkers in Hematology and Oncology
- Blood Disorders: Diagnosis and Treatment
- Cancer Genomics & Metabolomics
- Case Reports in Hematology
- Clinical Haematology
- Cord Blood Transplantation
- Digital Imaging in Hematology
- Haematology and Pharma Industry
- Hematologic Cancers
- Hematology and Cardio-Oncology
- Hematology Nursing
- Hematology: Diagnostics and Screening
- Hematopoietic Malignancies
- Organ Specific Cancer
- Pediatric Hematology
- Stem Cell Therapy
- Transfusion Medicines
- Vascular Bleeding Disorders